Gateway Wealth Partners LLC Sells 1,876 Shares of Pfizer Inc. (NYSE:PFE)

Gateway Wealth Partners LLC lessened its stake in shares of Pfizer Inc. (NYSE:PFE) by 20.7% during the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,176 shares of the biopharmaceutical company’s stock after selling 1,876 shares during the period. Gateway Wealth Partners LLC’s holdings in Pfizer were worth $201,000 at the end of the most recent reporting period.

Other hedge funds have also recently added to or reduced their stakes in the company. Wallace Capital Management Inc. boosted its holdings in shares of Pfizer by 7.4% in the 2nd quarter. Wallace Capital Management Inc. now owns 10,190 shares of the biopharmaceutical company’s stock valued at $285,000 after purchasing an additional 700 shares in the last quarter. Regal Investment Advisors LLC boosted its holdings in shares of Pfizer by 7.3% in the 2nd quarter. Regal Investment Advisors LLC now owns 282,398 shares of the biopharmaceutical company’s stock valued at $7,901,000 after purchasing an additional 19,091 shares in the last quarter. Quarry LP acquired a new stake in shares of Pfizer in the 2nd quarter valued at $31,000. Wallace Advisory Group LLC acquired a new stake in shares of Pfizer in the 2nd quarter valued at $434,000. Finally, William B. Walkup & Associates Inc. acquired a new stake in shares of Pfizer in the 2nd quarter valued at $1,100,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Down 0.5 %

Shares of PFE opened at $28.94 on Tuesday. The company has a market capitalization of $163.96 billion, a PE ratio of -482.25, a PEG ratio of 1.27 and a beta of 0.68. Pfizer Inc. has a 12 month low of $25.20 and a 12 month high of $34.11. The stock’s 50-day moving average price is $29.29 and its two-hundred day moving average price is $28.30. The company has a current ratio of 0.86, a quick ratio of 0.60 and a debt-to-equity ratio of 0.65.

Pfizer (NYSE:PFE) last announced its earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The firm had revenue of $13.28 billion for the quarter, compared to the consensus estimate of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The business’s quarterly revenue was up 2.1% compared to the same quarter last year. During the same period in the previous year, the business earned $0.67 EPS. On average, analysts anticipate that Pfizer Inc. will post 2.66 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on PFE. Barclays raised their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. Wells Fargo & Company raised their target price on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a report on Wednesday, July 31st. StockNews.com raised Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday, September 16th. Finally, Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. Eight research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.